Isorhapontigenin

Synonyms: 异丹叶大黄素
Isorhapontigenin 是一种具有口服活性的膳食多酚,作为强效抗氧化剂能够减弱活性氧 (ROS) 的生成,可促进 JUN 与 SESN2 启动子的 AP-1 位点结合、诱导 SESN2 转录、触发依赖 MAPK8 的 JUN 激活,并上调 PPAR-α、PGC-1α、CPT-1A 的表达以促进脂肪酸氧化,同时可诱导自噬 (autophagy)、细胞凋亡 (apoptosis) 及前脂肪细胞分化,抑制肿瘤生长、细胞侵袭、NF-κB 转录活性、P3K/Akt 信号通路、STAT1 磷酸化及 MMP-2 表达,并可减轻氧化应激、炎症细胞因子释放、甘油三酯蓄积,提升细胞内 ATP 水平并促进 Nrf2 核转位,从而改善脂肪组织的胰岛素敏感性、葡萄糖耐量,降低餐后血糖、胰岛素及游离脂肪酸水平,可用于膀胱癌、肝损伤、慢性阻塞性肺疾病、急性肺损伤和 2 型糖尿病的相关研究。
产品编号: MS-G76059 纯度: 99.82% CAS No.: 32507-66-7 分子式: C15H14O4 分子量: 258.27
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Isorhapontigenin 是一种具有口服活性的膳食多酚,作为强效抗氧化剂能够减弱活性氧 (ROS) 的生成,可促进 JUN 与 SESN2 启动子的 AP-1 位点结合、诱导 SESN2 转录、触发依赖 MAPK8 的 JUN 激活,并上调 PPAR-α、PGC-1α、CPT-1A 的表达以促进脂肪酸氧化,同时可诱导自噬 (autophagy)、细胞凋亡 (apoptosis) 及前脂肪细胞分化,抑制肿瘤生长、细胞侵袭、NF-κB 转录活性、P3K/Akt 信号通路、STAT1 磷酸化及 MMP-2 表达,并可减轻氧化应激、炎症细胞因子释放、甘油三酯蓄积,提升细胞内 ATP 水平并促进 Nrf2 核转位,从而改善脂肪组织的胰岛素敏感性、葡萄糖耐量,降低餐后血糖、胰岛素及游离脂肪酸水平,可用于膀胱癌、肝损伤、慢性阻塞性肺疾病、急性肺损伤和 2 型糖尿病的相关研究。

生物实验数据

生物活性 Isorhapontigenin is an orally active dietary polyphenol that acts as a potent antioxidant to attenuate reactive oxygen species (ROS) generation, promotes JUN binding to the AP-1 site of the SESN2 promoter to induce SESN2 transcription, triggers MAPK8-dependent JUN activation, and upregulates PPAR-α, PGC-1α, and CPT-1A expression to promote fatty acid oxidation, while also inducing autophagy, apoptosis, and preadipocyte differentiation, inhibiting tumor growth, cell invasion, NF-κB transcriptional activity, P3K/Akt signaling pathway, STAT1 phosphorylation, and MMP-2 expression, and alleviating oxidative stress, inflammatory cytokine release, and triglyceride accumulation, elevating intracellular ATP levels, and promoting Nrf2 nuclear translocation, thereby improving insulin sensitivity and glucose tolerance in adipose tissue and reducing postprandial blood glucose, insulin, and free fatty acid levels, and it can be used for research related to bladder cancer, liver injury, chronic obstructive pulmonary disease, acute lung injury, and type 2 diabetes.
IC50 & Target

CPT-1A

 

MMP-2

 

PPARα

 

PPARγ

 

FOXO1

 

IL-6

 

体外研究
(In Vitro)

Isorhapontigenin (1.25-40 μM; 24 h) 可在 UMUC3、T24T 和 HeLa 细胞中以剂量依赖的方式诱导自噬,且该自噬作用有助于其抑制 UMUC3 细胞的锚定非依赖性生长。
Isorhapontigenin (2.5-10 μM; 12-24 h) 可通过依赖 JUN 的机制上调 SESN2 的转录水平,该机制是 UMUC3 细胞中自噬诱导及锚定非依赖性生长抑制的必要条件。
Isorhapontigenin (10 μM; 12 h pre-APAP treatment, 24 h post-APAP treatment) 可通过上调 PPAR-α/PGC-1α/CPT-1A 信号通路,减轻对 AML12 细胞中 APAP 诱导的 FAO 失调。
Isorhapontigenin (1-100 μM;预孵育 1 h+刺激 24 h,预孵育 1 h+刺激 10-60 min) 可抑制原代人气道上皮细胞与 A549 细胞释放 IL-6 和 CXCL8,其对 IL-6 的 IC50 值为 17.3-19.7 μM,同时可抑制 NF-κB、AP-1 及 PI3K/Akt/FoxO3A 信号通路。
Isorhapontigenin (1-100 μM; 1 h pre-incubation + 30 min stimulation) 可浓度依赖性地降低经 IL-1β 刺激的 A549 细胞内的 ROS 水平。
Isorhapontigenin (5-15 μM; 12 h pretreatment + 12 h LPS stimulation) 可通过减少促炎介质和活性氧 (ROS) 的生成,对经 LPS 刺激的 RAW264.7 细胞发挥抗炎与抗氧化作用。
Isorhapontigenin (15 μM; 0-24 h direct treatment, 12 h pretreatment + 12 h LPS stimulation) 可在 RAW264.7 细胞中激活 Nrf2 通路,其抗炎/抗氧化作用依赖于 Nrf2 的激活。
Isorhapontigenin (25 μM; 6 days) 可通过提升 PPARγ 的活性与表达,促进 3T3-L1 前脂肪细胞的分化、增强其胰岛素敏感性并降低脂解作用。
Isorhapontigenin (25 μM; 0-12 h) 可通过减少抑制性磷酸化并延缓蛋白酶体降解,提高 3T3-L1 细胞中 PPARγ 的活性与稳定性。
Isorhapontigenin (10-20 μM; 24 h) 可分别特异性抑制 UMUC3 和 T24T 人侵袭性膀胱癌细胞的侵袭能力,且不会影响细胞迁移。
Isorhapontigenin (2.5-20 μM; 6-18 h) 可在人侵袭性膀胱癌 UMUC3 和 T24T 细胞中诱导 FOXO1 蛋白表达呈剂量和时间依赖性上调。
Isorhapontigenin (2.5-20 μM; 3-9 h) 可在转录水平上调人侵袭性膀胱癌细胞 UMUC3 和 T24T 中 foxo1的 mRNA 表达。
Isorhapontigenin (10 μM; 6-18 h) 可在人侵袭性膀胱癌细胞 UMUC3 中以时间依赖性方式增强 FOXO1 启动子活性。
Isorhapontigenin (2.5-10 μM; 12 h) 可在 UMUC3 人侵袭性膀胱癌细胞中以剂量依赖的方式抑制 STAT1 在 Tyr701 位点的磷酸化。
Isorhapontigenin (2.5-20 μM; 18 h) 可呈剂量依赖性地抑制人侵袭性膀胱癌细胞 UMUC3 和 T24T 中 MMP-2 蛋白的表达。

Cell Autophagy Assay

Cell Line: UMUC3, T24T, HeLa
Concentration: 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM
Incubation Time: 24 h
Result: Caused a dose-dependent increase in LC3-I to LC3-II conversion in UMUC3, T24T, and HeLa cells. Increased the percentage of GFP-LC3 puncta-positive cells and the number of puncta per cell in a dose-dependent manner in GFP-LC3-transfected UMUC3 cells.

Western Blot Analysis

Cell Line: UMUC3
Concentration: 2.5 μM, 5 μM, 10 μM
Incubation Time: 24 h
Result: Increased SESN2 and BECN1 expression at 2.5-10 μM in UMUC3 cells. Saw its induced LC3-II formation unaffected by BECN1 knockdown in UMUC3 cells. Had its LC3-II formation significantly attenuated in SESN2 knockdown UMUC3 cells. Saw its inhibitory effect on anchorage-independent growth of UMUC3 cells abolished when SESN2 was knocked down.

Western Blot Analysis

Cell Line: UMUC3
Concentration: 5 μM, 10 μM
Incubation Time: 6 h, 12 h, 24 h
Result: Increased MAPK8 phosphorylation in a dose-dependent manner. Had its induced JUN phosphorylation, SESN2 induction, LC3-II formation, SESN2 mRNA expression, and SESN2 promoter activity blocked when MAPK8 was knocked down. Saw its inhibitory effect on anchorage-independent growth of UMUC3 cells abolished when MAPK8 was knocked down.

Cell Differentiation Assay

Cell Line: 3T3-L1 preadipocytes
Concentration: 25 μM
Incubation Time: 6 days (differentiation)
Result: Promoted lipid accumulation (quantified by Oil Red O staining optical density at 490 nm). Significantly increased mRNA and protein expression of PPARγ target genes (CEBPα, FAS, FABP4, GLUT4) and PPARγ itself. Enhanced insulin-stimulated glucose uptake (1.5-fold over basal). Reduced mRNA and protein levels of hormone-sensitive lipase (HSL).

Cell Invasion Assay

Cell Line: UMUC3, T24T human invasive bladder cancer cells
Concentration: 10 μM (UMUC3 cells); 20 μM (T24T cells)
Incubation Time: 24 h (UMUC3, T24T cells)
Result: Reduced relative invasion rate of UMUC3 cells by 63.1% and T24T cells by 61.2% compared to vehicle control; did not affect cell migration under the same conditions.

Western Blot Analysis

Cell Line: UMUC3, T24T human invasive bladder cancer cells
Concentration: 2.5-10 μM (UMUC3 cells, dose-response); 10-20 μM (T24T cells, dose-response); 10 μM (UMUC3 cells, time-course)
Incubation Time: 12 h (UMUC3, T24T cells, dose-response); 6-18 h (UMUC3 cells, time-course)
Result: Induced FOXO1 protein expression in a dose-dependent manner in UMUC3 and T24T cells; caused a gradual increase in FOXO1 protein level.

RT-PCR

Cell Line: UMUC3, T24T human invasive bladder cancer cells
Concentration: 2.5-10 μM (UMUC3 cells, dose-response); 10 μM (UMUC3 cells, time-course); 10-20 μM (T24T cells, dose-response)
Incubation Time: 6 h (UMUC3, T24T cells, dose-response); 3-9 h (UMUC3 cells, time-course)
Result: Upregulated endogenous foxo1 mRNA expression in a dose-dependent manner in UMUC3 and T24T cells, and in a time-dependent manner in UMUC3 cells; did not affect exogenous flag-foxo1 mRNA expression.

Western Blot Analysis

Cell Line: UMUC3 human invasive bladder cancer cells
Concentration: 2.5-10 μM
Incubation Time: 12 h
Result: Dramatically inhibited STAT1 phosphorylation at Tyr701 in a dose-dependent manner without affecting total STAT1 protein expression.

Western Blot Analysis

Cell Line: UMUC3, T24T human invasive bladder cancer cells
Concentration: 2.5-10 μM (UMUC3 cells); 10-20 μM (T24T cells)
Incubation Time: 18 h (UMUC3, T24T cells)
Result: Profoundly inhibited MMP-2 protein expression in a dose-dependent manner in both UMUC3 and T24T cells.

RT-PCR

Cell Line: T24T human invasive bladder cancer cells
Concentration: 10-20 μM
Incubation Time: 18 h
Result: Attenuated MMP-2 mRNA level in a dose-dependent manner; did not affect MMP-9 mRNA level.
体内研究
(In Vivo)

Isorhapontigenin (150 mg/kg; daily) 可显著抑制注射 T24T 细胞的裸鼠体内异种移植瘤的生长。
Isorhapontigenin (25-50 mg/kg; i.g;单次给药或者一天一次,连续 3 天) 通过减少细胞凋亡、炎症反应与氧化应激,同时恢复脂肪酸氧化,缓解对乙酰氨基酚诱导的小鼠肝损伤;25 mg/kg 和 50 mg/kg 剂量均显示出有效性。
Isorhapontigenin (51.6 mg/kg; p.o.; daily; 7 days) 可通过减轻炎症反应与氧化应激,有效改善小鼠体内由 LPS 诱导的急性肺损伤。
Isorhapontigenin (25 mg/kg; i.p.; daily; 5 weeks) 可通过调控 PPARγ 改善葡萄糖与胰岛素稳态、增强胰岛素敏感性并调节脂肪组织功能,从而缓解 db/db 小鼠的 2 型糖尿病。
Isorhapontigenin (150 mg/kg/天;饮用水给药;每日给药;持续 20 周) 可抑制 N-Butyl-N-(4-hydroxybutyl)nitrosamine (BBN) (MS-O57586) 诱导的 C57BL/6J 小鼠侵袭性膀胱癌的形成,经其处理的小鼠中仅 16.7%发展为高级别肌层浸润性病变,而仅用 BBN 处理的对照组小鼠的该比例为 100%。

Animal Model: C57BL/6 (male, 6-8 weeks old; Acetaminophen-induced liver injury model)
Dosage: 25 mg/kg; 50 mg/kg
Administration: i.g. (once, 1 hour after acetaminophen); i.g. (once daily for 3 consecutive days, acetaminophen on day 3); i.g. (once, 1 hour before acetaminophen); i.g. (once, 3 hours after acetaminophen)
Result: Significantly reduced serum ALT, AST, and LDH levels, centrilobular necrosis area, TUNEL-positive cells, C-PARP expression, serum TNF-α and IL-6 levels, liver MDA levels, and increased liver CAT levels at 25 and 50 mg/kg (post-treatment) compared to acetaminophen alone; reduced lipid accumulation (Oil Red O and BODIPY staining), serum and liver TG levels, increased liver ATP content and FAO activity, and upregulated PPAR-α, PGC-1α, and CPT-1A protein expression at 50 mg/kg (pre-treatment).
Animal Model: C57BL/6 (male, 6-8 weeks old, 20-25 g, LPS-challenged)
Dosage: 51.6 mg/kg
Administration: p.o.; daily; 7 days
Result: Reduced LPS-induced lung injury score, myeloperoxidase (MPO) activity in lung tissues, lung wet/dry weight ratio, and protein concentration in bronchoalveolar lavage fluid (BALF); suppressed LPS-induced increases in BALF concentrations of IL-1β, IL-6, and TNF-α; inhibited p-NF-κB p65 expression and IκB degradation in lung tissues; reduced malondialdehyde (MDA) formation in lung tissues; restored superoxide dismutase (SOD) and glutathione (GSH) activities in lung tissues.
Animal Model: db/db mice (male, 8 weeks old at treatment start, genetically diabetic model)
Dosage: 25 mg/kg
Administration: i.p.; daily; 5 weeks
Result: Reduced postprandial fasting glucose levels by 17.2% after 2 weeks and 40.0% after 5 weeks; reduced insulin levels by 23.2% after 5 weeks; reduced plasma FFA levels by 34.7% after 5 weeks compared to vehicle controls; improved glucose disposal during GTT; enhanced exogenous-insulin-stimulated glucose uptake during ITT; significantly reduced water intake; reduced white adipose tissue adipocyte diameters; significantly increased mRNA expression of PPARγ and its target genes (Fabp4, Glut4, Fas); significantly reduced mRNA and protein levels of HSL; significantly increased insulin-stimulated Akt phosphorylation in white adipose tissue.
Animal Model: C57BL/6J (male, 5-6 weeks old) injected with N-Butyl-N-(4-hydroxybutyl)nitrosamine
Dosage: 150 mg/kg/day
Administration: oral via drinking water; daily; 20 weeks
Result: Reduced the incidence of BBN-induced high-grade muscle-invasive bladder cancer from 100% (12/12 mice) to 16.7% (2/12 mice); caused 7 cases of papillomas and 3 cases of low-grade non-muscle-invasive bladder cancer in treated mice; up-regulated FOXO1 protein expression and down-regulated MMP-2 protein expression in mouse bladder tissues.
性状 固体
颜色 White to yellow

化学信息

分子量 258.27
分子式 C15H14O4
CAS No. 32507-66-7
别名 异丹叶大黄素

储存&溶解度

体内实验配方
5% DMSO+40% PEG300+5% Tween-80+50% Saline: 2.5 mg/mL: 2.5 mg/mL (9.68 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, sealed storage, away from moisture and light

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (193.60 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.8719 mL19.3596 mL38.7192 mL96.7979 mL
5 mM0.7744 mL3.8719 mL7.7438 mL19.3596 mL
10 mM0.3872 mL1.9360 mL3.8719 mL9.6798 mL
15 mM0.2581 mL1.2906 mL2.5813 mL6.4532 mL
20 mM0.1936 mL0.9680 mL1.9360 mL4.8399 mL
25 mM0.1549 mL0.7744 mL1.5488 mL3.8719 mL
30 mM0.1291 mL0.6453 mL1.2906 mL3.2266 mL
40 mM0.0968 mL0.4840 mL0.9680 mL2.4199 mL
50 mM0.0774 mL0.3872 mL0.7744 mL1.9360 mL
60 mM0.0645 mL0.3227 mL0.6453 mL1.6133 mL
80 mM0.0484 mL0.2420 mL0.4840 mL1.2100 mL
100 mM0.0387 mL0.1936 mL0.3872 mL0.9680 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础